Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States.

ABSTRACT:

Background

Neoadjuvant chemotherapy (NACT) for the treatment of muscle-invasive bladder cancer (MIBC) remains underutilized in the United States despite evidence supporting its use.

Objectives

To examine the perioperative chemotherapy management of patients with MIBC by medical oncologists (MedOncs) to move toward standardization of practice

Participants and methods

A 26-question survey was emailed to 92 MedOncs belonging to the Bladder Cancer Advocacy Network or the American Society of Clinical Oncology for completion from May to October 2011 RESULTS: A total of 83 MedOncs completed the survey: 52% were based in academic centers. Most referrals were from urologists (79%). NACT for treatment of MIBC and high-grade upper-tract urothelial carcinoma is offered by 80% and

SUBMITTER: Apolo AB 

PROVIDER: S-EPMC6771274 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature